FDA receives additional data for Tavneos lifts Amgen stock toward $402.79 resistance

Traders Union
All News
Stocks
Amgen jumps 4.36% to $392.5 today

Highlights

Amgen submitted additional data to the FDA to avert Tavneos' withdrawal, addressing regulatory risk for its drug portfolio.
This move alleviates immediate market access concerns over Tavneos, helping stabilize future revenue expectations for Amgen.
AMGN maintains a bullish structure with strong momentum; price forecast projects a $382.21–$402.79 range over the next 2–3 days.

Regulatory data submission boosts sentiment as market access concerns ease

Amgen submitted further data to the FDA supporting Tavneos after the agency proposed its withdrawal from the U.S. market, according to Quiverquant. By taking this step, the company addresses regulatory uncertainties that could impact its drug portfolio, helping to preserve future revenue from Tavneos. This action has attracted buying interest as it alleviates immediate concerns over market access for one of Amgen's therapies.

Momentum moderates as oscillators signal cooling in overbought setup

On the h1 chart, price is positioned above both the MA-20 of $381.73 and the MA-50 of $372.56, with daily price action also sustained above the MA-200 at $341.92. Immediate support is identified at the Ichimoku Kijun level of $381.28. Momentum signals confirm this constructive setup: MACD and ADX remain in Buy mode, and RSI continues to indicate a Buy while approaching higher levels. CCI points to ongoing buyer strength, although Stoch RSI is neutral. Bull/Bear Power is in overbought territory, showing persistent buyer dominance. The Awesome Oscillator is neutral, offering little confirmation for the current trend. Despite a 17.74-point opening gap and moderate volatility, some oscillators now signal either neutral or overbought conditions, which may indicate cooling momentum.

Upside favored as consolidation expected within defined volatility band

Over the next 2–3 trading days, the forecasted range for AMGN stands between $382.21 and $402.79, a volatility band relative to current levels. The probability of further upside is assessed as very high, with downside risk considered low. The base case projects that AMGN will consolidate within this range; a clear break above $402.79 would likely accelerate upward momentum, while a drop below $382.21 could trigger a more significant retracement.

Viktoras Karapetjanc, expert at Traders Union, notes that Amgen's decisive move to address regulatory risks around Tavneos removes a significant overhang from the stock. He believes this builds positive sentiment among investors and reinforces confidence in Amgen's revenue outlook. Current technical and momentum signals remain supportive, with the price holding above all key moving averages. The analyst sees a strong probability of continued consolidation with an upward bias in the short term. "Amgen’s proactive handling of FDA concerns has reignited market optimism, and I expect buyer demand to remain elevated as long as price stays above $382.21."

Earlier, analysts noted that Amgen maintained a strong bullish outlook underpinned by sustained momentum and favorable technicals. The latest regulatory developments around Tavneos further reinforce this constructive thesis, with near-term focus now on AMGN’s ability to hold above $382.21 to avoid a deeper pullback.

Source of Data: AMGN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.